Haemodialysis (HD) utilizes the bidirectional properties of semipermeable membranes to remove uraemic toxins from blood while simultaneously replenishing electrolytes and buffers to correct metabolic acidosis. However, the nonspecific size-dependent transport across membranes also means that certain useful plasma constituents may be removed from the patient (together with uraemic toxins), or toxic compounds, e.g., endotoxin fragments, may accompany electrolytes and buffers of the dialysis fluids into blood and elicit severe biological reactions.

In this webinar, the mechanisms, and implications of these undesirable transport processes, focusing mainly on loss of albumin and endotoxin retention, that are inherent to all HD therapies and propose approaches to mitigate the effects of such transport will be introduced and discussed.

Event Date: 11/15/2022